Blockade of PD-1 or CTLA-4 can contribute to the inhibition of osteosarcoma, but, in a phase II trial, only 5% of patients with osteosarcoma were relieved by PD-1 inhibitor-pembrolizumab (76). The gene discussed is PDCD1; the disease is osteosarcoma.